Have you stopped receiving our weekly e-newsletter?

Europe

Author: Joe McAweaneyPublished: 12 July 2018

Prep: Cook: Serves:

Due to recent changes in EU law, you must ‘opt-in’ to continue to receive our e-newsletter

On 25 May 2018 General Data Protection Regulation (GDPR) laws were passed by the European Union, significantly changing the ways in which businesses and public sector organisations must handle data.

The new laws mean that all consumer information held before this date must be deleted, meaning that people must ‘opt-in’ to keep receiving communications from organisations. For Parkinson’s Life, this means that if you want to keep receiving our weekly e-mail newsletter you must let us know – regardless of whether you have signed up in the past or not. Legally, we must delete your data and cannot communicate with you if you have not signed up.

To sign up, please click ‘subscribe’ in the top right hand corner of our website and fill out the form.

We are very proud of the work we do here at Parkinson’s Life, and are looking forward to communicating with as many of you as possible in the future.

Last Month

Next Month

Go Back

Share this story

Comments

In my country

Supporting 100,000 Australians with Parkinson’s

We spoke to the CEO of Parkinson’s Australia

Why I promise to make poetry, not Parkinson’s disease, my daily challenge

Parkinson’s poet crafts a piece per day for year-long project

The comic book that explains Parkinson’s to young children

Children’s comic book: ‘Medikidz Explains Parkinson’s Disease’

Plant-based compounds could treat chronic pain in Parkinson’s, study finds

A six-year study has found that chronic pain in people with Parkinson’s is linked to a gene involved with how the brain responds to cannabis compounds. The investigation examined why some people with the condition experience persistent pain – and the impact it has on their work, daily life and social relationships. Conducted by researchers at Manchester’s Salford Royal Foundation Trust, UK, and funded by Parkinson’s UK, it is the largest study to investigate chronic pain in people with Parkinson’s. Dr Monty Silverdale, consultant neurologist at Greater Manchester Centre, said: “This study is significant because it shows the important role of genetics in chronic pain in Parkinson’s. “Our findings suggest that cannabis-based compounds may be worth investigating as a treatment for pain in Parkinson’s.”

Could playing table tennis help reduce Parkinson’s symptoms?

Researchers at Fukuoka University, Japan, have found that playing table tennis may help alleviate motor symptoms in Parkinson’s. As part of the study, 12 people with Parkinson’s with an average age of 73 played a five-hour session of table tennis every week for a period of six months. The sessions were developed specifically for people with the condition by experienced table tennis players from the university’s department of sports science. The participants were evaluated after three months and at the end of the study. At both evaluations, participants had reduced symptoms – showing improvement in speech, handwriting, walking and hand tremors. Two participants reported side-effects of backache and falling. Study author Ken-ichi Inoue, MD, of Fukuoka University said: “While this study is small, the results are encouraging because they show ping pong, a relatively inexpensive form of therapy, may improve some symptoms of Parkinson’s disease. A much larger study is…

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

Researchers have discovered that a molecule called BT13 could have potential to treat Parkinson’s. The study, conducted by scientists from the University of Helsinki, Finland, found that mice injected with the BT13 molecule had an increase in dopamine levels in the brain. Their findings also suggested that the molecule could lead to a new drug treatment to protect the brain cells that produce dopamine. Dopamine helps coordinate movement, but people with Parkinson’s have normally lost between 70 and 80% of the brain cells that produce the neurotransmitter when they are diagnosed with the condition. Professor David Dexter, Deputy Director of Research at Parkinson’s UK – which co-funded the study – said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms. “More research is needed to turn BT13 into a treatment to be tested in clinical trials, to…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

Have you stopped receiving our weekly e-newsletter?

Europe

Author: Joe McAweaneyPublished: 12 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

In my country

Supporting 100,000 Australians with Parkinson’s

Perspectives

Why I promise to make poetry, not Parkinson’s disease, my daily challenge

Resources & Tools

The comic book that explains Parkinson’s to young children

Plant-based compounds could treat chronic pain in Parkinson’s, study finds

Could playing table tennis help reduce Parkinson’s symptoms?

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

{title}

Subscribe

Have you stopped receiving our weekly e-newsletter?

Europe

Author: Joe McAweaneyPublished: 12 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

In my country

Supporting 100,000 Australians with Parkinson’s

Perspectives

Why I promise to make poetry, not Parkinson’s disease, my daily challenge

Resources & Tools

The comic book that explains Parkinson’s to young children

Plant-based compounds could treat chronic pain in Parkinson’s, study finds

Could playing table tennis help reduce Parkinson’s symptoms?

‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s

{title}

Subscribe

Sign in